

# Joseph M Blondeau

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8806554/joseph-m-blondeau-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54  
papers

1,722  
citations

18  
h-index

41  
g-index

68  
ext. papers

2,051  
ext. citations

3.9  
avg, IF

5.06  
L-index

#	Paper	IF	Citations
54	Urinary tract infection in a human male patient with transmission from the family dog. <i>Journal of Chemotherapy</i> , <b>2021</b> , 1-4	2.3	3
53	Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6. <i>Clinical Ophthalmology</i> , <b>2021</b> , 15, 4419-4430	2.5	
52	Antimicrobial Resistance <b>2021</b> , 163-174		
51	Clinical microbiology laboratories and COVID-19: an interview with Joseph Blondeau. <i>Future Microbiology</i> , <b>2021</b> , 16, 615-618	2.9	1
50	Recovery of borderline oxacillin-resistant (BORSP) from bone and soft tissue of a rheumatoid arthritis patient with severe osteoporosis: transmission from the family dog. <i>Journal of Chemotherapy</i> , <b>2021</b> , 33, 348-353	2.3	2
49	Diagnostic clinical microbiology. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , <b>2021</b> , 44, 250-269	1.4	1
48	Methicillin-resistant replication in the presence of high ( $\beta 2 \mu\text{g/ml}$ ) drug concentration of vancomycin as seen by electron microscopy. <i>Journal of Chemotherapy</i> , <b>2020</b> , 32, 179-187	2.3	
47	Bacteremia with in a 4 month old pediatric oncology patient. <i>Journal of Chemotherapy</i> , <b>2020</b> , 32, 260-262	2.3	6
46	Persistent infection with in an adult oncology patient with transmission from a family dog. <i>Journal of Chemotherapy</i> , <b>2020</b> , 32, 151-155	2.3	6
45	In vitro killing of canine strains of <i>Staphylococcus pseudintermedius</i> and <i>Escherichia coli</i> by cefazolin, cefovecin, doxycycline and pradofloxacin over a range of bacterial densities. <i>Veterinary Dermatology</i> , <b>2020</b> , 31, 187-e39	1.8	2
44	Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6. <i>PLoS ONE</i> , <b>2020</b> , 15, e0237603	3.7	5
43	A pilot study on the comparative minimum inhibitory and mutant prevention concentration values for moxifloxacin and pradofloxacin against canine and human isolates of <i>Staphylococcus pseudintermedius</i> and <i>S. schleiferi</i> . <i>Veterinary Dermatology</i> , <b>2019</b> , 30, 481-e142	1.8	0
42	Characterization of carbapenem-resistant and XDR <i>Pseudomonas aeruginosa</i> in Canada: results of the CANWARD 2007-16 study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, iv32-iv38	5.1	14
41	The in vitro antibacterial activity of the anthelmintic drug oxiclozanide against common small animal bacterial pathogens. <i>Veterinary Dermatology</i> , <b>2019</b> , 30, 314-e87	1.8	
40	International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats. <i>Veterinary Journal</i> , <b>2019</b> , 247, 8-25	2.5	105
39	Reporting elevated vancomycin minimum inhibitory concentration in methicillin-resistant <i>Staphylococcus aureus</i> : consensus by an International Working Group. <i>Future Microbiology</i> , <b>2019</b> , 14, 345-352	2.9	13
38	Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens <i>Actinobacillus pleuropneumoniae</i> , <i>Pasteurella multocida</i> and <i>Streptococcus suis</i> . <i>PLoS ONE</i> , <b>2019</b> , 14, e0210154	3.7	14

37	Epidemiology of bacterial corneal ulcers at tertiary centres in Vancouver, B.C. <i>Canadian Journal of Ophthalmology</i> , <b>2018</b> , 53, 330-336	1.4	13
36	In vitro activity of tigecycline and comparators (2014-2016) among key WHO Priority pathogens and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study. <i>International Journal of Antimicrobial Agents</i> , <b>2018</b> , 52, 474-484	14.3	22
35	Tetrasodium EDTA Is Effective at Eradicating Biofilms Formed by Clinically Relevant Microorganisms from Patients Central Venous Catheters. <i>MSphere</i> , <b>2018</b> , 3,	5	12
34	Susceptibility testing and reporting of new antibiotics with a focus on tedizolid: an international working group report. <i>Future Microbiology</i> , <b>2017</b> , 12, 1523-1532	2.9	4
33	Comparative in vitro killing of canine strains of Staphylococcus pseudintermedius and Escherichia coli by ceftiofur, cefazolin, doxycycline and pradofloxacin. <i>Veterinary Dermatology</i> , <b>2016</b> , 27, 267-e63	1.8	4
32	Besifloxacin in the management of bacterial infections of the ocular surface. <i>Canadian Journal of Ophthalmology</i> , <b>2015</b> , 50, 184-91	1.4	11
31	Bactericidal effects of various concentrations of enrofloxacin, florfenicol, tilimicosin phosphate, and tulathromycin on clinical isolates of Mannheimia haemolytica. <i>American Journal of Veterinary Research</i> , <b>2015</b> , 76, 860-8	1.1	5
30	Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). <i>Veterinary Dermatology</i> , <b>2014</b> , 25, 163-e43	1.8	135
29	Pradofloxacin: a novel veterinary fluoroquinolone for treatment of bacterial infections in cats. <i>Veterinary Journal</i> , <b>2014</b> , 201, 207-14	2.5	9
28	Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 631-5	5.1	28
27	Do we really understand what we want or need out of antimicrobial stewardship programs?. <i>Clinical Practice (London, England)</i> , <b>2013</b> , 10, 5-9	3	2
26	In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat. <i>Veterinary Microbiology</i> , <b>2012</b> , 155, 284-90	3.3	18
25	Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilimicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica. <i>Veterinary Microbiology</i> , <b>2012</b> , 160, 85-90	3.3	32
24	Advances in laboratory diagnostic technologies in clinical microbiology and what this means for clinical practice. <i>Clinical Practice (London, England)</i> , <b>2012</b> , 9, 347-352	3	8
23	Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases. <i>Veterinary Medicine International</i> , <b>2011</b> , 2011, 263768	1.5	192
22	New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. <i>Veterinary Dermatology</i> , <b>2009</b> , 20, 383-96	1.8	75
21	Role of gemifloxacin in the management of community-acquired lower respiratory tract infections. <i>International Journal of Antimicrobial Agents</i> , <b>2008</b> , 31, 299-306	14.3	9
20	Hospital-based strategies to reduce antibiotic resistance: are they valid in the community setting?. <i>Expert Review of Anti-Infective Therapy</i> , <b>2007</b> , 5, 53-9	5.5	4

19	Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of <i>Haemophilus influenzae</i> . <i>Eye and Contact Lens</i> , <b>2007</b> , 33, 161-4 <sup>2</sup>	3.2	9
18	Application of two methods to determine killing of <i>Streptococcus pneumoniae</i> by various fluoroquinolones. <i>Journal of Chemotherapy</i> , <b>2006</b> , 18, 366-72	2.3	6
17	Mutant prevention concentration for ciprofloxacin and levofloxacin with <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , <b>2006</b> , 27, 120-4	14.3	54
16	Antibiotic dosing: do we dose to cure the individual or do we treat the greater societal needs?. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2005</b> , 2, 511-516		7
15	Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2005</b> , 2, 357-373		
14	Management of community-acquired lower respiratory tract infections: gemifloxacin, a new economic paradigm. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2005</b> , 2, 357-373		
13	Gemifloxacin: a new fluoroquinolone. <i>Expert Opinion on Pharmacotherapy</i> , <b>2004</b> , 5, 1117-52	4	15
12	Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option. <i>Drugs</i> , <b>2004</b> , 64, 611-28	12.1	30
11	Fluoroquinolones: mechanism of action, classification, and development of resistance. <i>Survey of Ophthalmology</i> , <b>2004</b> , 49 Suppl 2, S73-8	6.1	206
10	Mutant prevention concentration of gemifloxacin for clinical isolates of <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 440-1	5.9	36
9	Quinupristin/dalfopristin. <i>Expert Opinion on Pharmacotherapy</i> , <b>2002</b> , 3, 1341-64	4	11
8	The evolution and role of macrolides in infectious diseases. <i>Expert Opinion on Pharmacotherapy</i> , <b>2002</b> , 3, 1131-51	4	31
7	Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. <i>Expert Opinion on Pharmacotherapy</i> , <b>2001</b> , 2, 317-35	4	31
6	Mutant prevention concentrations of fluoroquinolones for clinical isolates of <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2001</b> , 45, 433-8	5.9	266
5	Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. <i>Expert Opinion on Investigational Drugs</i> , <b>2001</b> , 10, 213-37	5.9	13
4	A review of clinical trials with fluoroquinolones with an emphasis on new agents. <i>Expert Opinion on Investigational Drugs</i> , <b>2000</b> , 9, 383-413	5.9	19
3	Gatifloxacin: a new fluoroquinolone. <i>Expert Opinion on Investigational Drugs</i> , <b>2000</b> , 9, 1877-95	5.9	14
2	A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1999</b> , 43 Suppl B, 1-11	5.1	136

- 1 In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group. *Journal of Antimicrobial Chemotherapy*, **1999**, 43 Suppl A, 3-23 5.1 20